Durable natural killer cell responses after heterologous two-dose Ebola vaccination

Helen R Wagstaffe, Giada Susannini, Rodolphe Thiébaut, Laura Richert, Yves Lévy, Viki Bockstal, Jeroen N Stoop, Kerstin Luhn, Macaya Douoguih, Eleanor Riley, Christine Lacabaratz, Martin R. Goodier

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Natural killer (NK) cells are implicated among immune effectors after vaccination against viral pathogens, including Ebola virus. The two-dose heterologous Ebola virus vaccine regimen, adenovirus type 26.ZEBOV followed by modified vacciniaAnkara-BN-Filo (EBOVAC2 consortium, EU Innovative Medicines Initiative), inducesNK cell activation and anti-Ebola glycoprotein (GP) antibody-dependent NK cellactivation post-dose 1, which is further elevated post-dose 2. Here, in a multi-centre,phase 2 clinical trial (EBL2001), we demonstrate durable ex vivo NK cell activation180 days after dose 2, with responses enriched in CD56bright NK cells. In vitroantibody-dependent responses to immobilised Ebola GP increased after dose 1 andremained elevated compared to pre-vaccination levels in serum collected 180 days later. Peak NK cell responses were observed post-dose 2 and NK cell IFN-responses remained significantly elevated 180 days post-dose 2. Individual variation in NK cell responses is influenced by both anti-Ebola GP antibody concentrationsand intrinsic inter-individual differences in NK cell functional capacity. In summary,this study demonstrates durable NK cell responses after Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccination and could inform immunological evaluation of future iterations of the vaccine regimen and vaccination schedules.
Original languageEnglish
Article number19
Number of pages10
Journalnpj Vaccines
Volume6
DOIs
Publication statusPublished - 29 Jan 2021

Keywords / Materials (for Non-textual outputs)

  • ebola
  • vaccine
  • natural killer cell
  • antibody

Fingerprint

Dive into the research topics of 'Durable natural killer cell responses after heterologous two-dose Ebola vaccination'. Together they form a unique fingerprint.

Cite this